ADARx Pharmaceuticals, Inc.
NASDAQ:ADRXBiotechnology
+$0.13 today
- Market cap
- $1.42B
- Beta
- 0.00
Volume 0.65M
Average 1.06M
ADRX Deferred Revenue
Payments received for goods or services the company will deliver within the next year.
Deferred Revenue history
Currency unavailable · from the balance sheet
No Deferred Revenue data reported for this period type.
Deferred Revenue vs competitors
How ADRX compares with its peers on the latest reported figures
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | €19.63M EUR | -5.6% | — | 19.8% | |
| Mar 2026 | $10.07M USD | -44.6% | -7.2% | 2.3% | |
| Mar 2026 | $9.4M USD | -83.6% | +12.1% | 1.6% | |
| Mar 2026 | $9.34M USD | — | — | 3.2% | |
| Mar 2026 | $7.61M USD | -49.6% | -38.9% | 3.1% | |
| Mar 2026 | $7.32M USD | -10.9% | — | 2.5% | |
| Mar 2026 | $2M USD | -52.9% | -51.0% | 0.8% | |
| Mar 2026 | $0 USD | -100.0% | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
ADRXADARx Pharmaceuticals, Inc. | — | — | — | — | — |
| Peer median (excluding ADRX) | — | -49.6% | -23.0% | 2.3% | |
Competitors are the stored peer set for ADRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
ADARx Pharmaceuticals, Inc.
NASDAQ:ADRX
Intrinsic Alpha fair value
Locked
Current Price
$12.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.